TY - JOUR
T1 - Interobserver agreement of the modified Paris classification and histology prediction of colorectal lesions in patients with inflammatory bowel disease
AU - Guerrero Vinsard, Daniela
AU - Bruining, David H.
AU - East, James E.
AU - Ebner, Derek
AU - Kane, Sunanda V.
AU - Kisiel, John B.
AU - Leighton, Jonathan A.
AU - Lennon, Ryan J.
AU - Loftus, Edward V.
AU - Malik, Talha
AU - Picco, Michael F
AU - Raffals, Laura
AU - Ramos, Guilherme P.
AU - Santiago, Priscila
AU - Coelho-Prabhu, Nayantara
N1 - Funding Information:
DISCLOSURE: The following authors disclosed financial relationships: D. H. Bruining: Advisory board for Janssen Pharmaceutical; research support from Medtronics and Takeda. J. E. East: Clinical advisory board for Paion and Satisfai Health; shared stock options in Satisfai Health; speaker for Falk, Jannsen, and Medtronic. S. V. Kane: Consultant for Boerhinger Ingelheim, Bristol Meyers Squibb, Gilead, Janssen, Kinetix Health, InveniAI, Seres Therapeutics, TechLab, and Takeda; scientific advisory board for PredictaMed. J. B. Kisiel: Named inventor with Mayo Clinic with intellectual property licensed to Exact Sciences; research support, product royalty, and intellectual property license from Exact Sciences. E. V. Loftus Jr: Consultant for AbbVie, Amgen, Arena, Boehringer Ingelheim, Bristol-Myers Squibb, CALIBR, Celgene, Eli Lilly, Fresenius Kabi, Genentech, Gilead, Gossamer Bio, Iterative Scopes, Janssen, Morphic, Ono Pharma, Pfizer, Protagonist, Scipher, Sun Pharma, Surrozen, Takeda, and UCB; research support from AbbVie, Bristol-Myers Squibb, Celgene/Receptos, Genentech, Gilead, Gossamer Bio, Janssen, Pfizer, Takeda, Theravance, and UCB; shareholder in Exact Sciences. L. Raffals: Advisory board for Janssen Pharmaceuticals. All other authors disclosed no financial relationships. Research support for this study was provided by the Mayo Clinic CTSA through grant number UL1 TR000135 from the National Center for Advancing Translational Sciences, a component of the National Institutes of Health.
Publisher Copyright:
© 2022 American Society for Gastrointestinal Endoscopy
PY - 2023
Y1 - 2023
N2 - Background and Aims: SCENIC (International Consensus Statement on Surveillance and Management of Dysplasia in IBD) guidelines recommend that visible dysplasia in patients with longstanding inflammatory bowel disease (IBD) should be endoscopically characterized using a modified Paris classification. This study aimed to determine the interobserver agreement (IOA) of the modified Paris classification and endoscopists’ accuracy for pathology prediction of IBD visible lesions. Methods: One hundred deidentified endoscopic still images and 30 videos of IBD visible colorectal lesions were graded by 10 senior and 4 trainee endoscopists from 5 tertiary care centers. Endoscopists were asked to assign 4 classifications for each image: the standard Paris classification, modified Paris classification, pathology prediction, and lesion border. Agreement was measured using Light's kappa coefficient. Consensus of ratings was assessed according to strict majority. Results: The overall Light's kappa for all study endpoints was between .32 and .49. In a subgroup analysis between junior and senior endoscopists, Light's kappa continued to be less than .6 with a slightly higher agreement among juniors. Lesions with the lowest agreement and no consensus were mostly classified as Is, IIa, and mixed Paris classification and sessile and superficial elevated for modified Paris classification. Endoscopist accuracy for prediction of dysplastic, nondysplastic, and serrated pathology was 77%, 56%, and 30%, respectively. There was a strong association (P < .001) between the given morphology classification and the predicted pathology with Ip lesions carrying a much lower expectation of dysplasia than Is/IIc/III and mixed lesions. The agreement for border prediction was .5 for junior and .3 for senior endoscopists. Conclusions: This study demonstrates very low IOA for Paris and modified Paris classifications and low accuracy and IOA for lesion histopathology prediction. Revisions of these classifications are required to create a clinically useful risk stratification tool and enable eventual application of augmented intelligence tools.
AB - Background and Aims: SCENIC (International Consensus Statement on Surveillance and Management of Dysplasia in IBD) guidelines recommend that visible dysplasia in patients with longstanding inflammatory bowel disease (IBD) should be endoscopically characterized using a modified Paris classification. This study aimed to determine the interobserver agreement (IOA) of the modified Paris classification and endoscopists’ accuracy for pathology prediction of IBD visible lesions. Methods: One hundred deidentified endoscopic still images and 30 videos of IBD visible colorectal lesions were graded by 10 senior and 4 trainee endoscopists from 5 tertiary care centers. Endoscopists were asked to assign 4 classifications for each image: the standard Paris classification, modified Paris classification, pathology prediction, and lesion border. Agreement was measured using Light's kappa coefficient. Consensus of ratings was assessed according to strict majority. Results: The overall Light's kappa for all study endpoints was between .32 and .49. In a subgroup analysis between junior and senior endoscopists, Light's kappa continued to be less than .6 with a slightly higher agreement among juniors. Lesions with the lowest agreement and no consensus were mostly classified as Is, IIa, and mixed Paris classification and sessile and superficial elevated for modified Paris classification. Endoscopist accuracy for prediction of dysplastic, nondysplastic, and serrated pathology was 77%, 56%, and 30%, respectively. There was a strong association (P < .001) between the given morphology classification and the predicted pathology with Ip lesions carrying a much lower expectation of dysplasia than Is/IIc/III and mixed lesions. The agreement for border prediction was .5 for junior and .3 for senior endoscopists. Conclusions: This study demonstrates very low IOA for Paris and modified Paris classifications and low accuracy and IOA for lesion histopathology prediction. Revisions of these classifications are required to create a clinically useful risk stratification tool and enable eventual application of augmented intelligence tools.
UR - http://www.scopus.com/inward/record.url?scp=85148850332&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85148850332&partnerID=8YFLogxK
U2 - 10.1016/j.gie.2022.11.006
DO - 10.1016/j.gie.2022.11.006
M3 - Article
C2 - 36402202
AN - SCOPUS:85148850332
SN - 0016-5107
JO - Gastrointestinal Endoscopy
JF - Gastrointestinal Endoscopy
ER -